Very good point! I think I saw somewhere that ~75% of new HIV cases are cc5 - not sure he saw that.

"sometimes companies do not charge patients under the patient assistance programs designed for indigent patients." I'm fully aware of that, but what % of patients qualify as indigent...5%?...10%?

In a previous post, the comment was made that "it will be very convenient to get your IV of Ibalizumab. The company is setting up a program where the IV will come to you at home, at work or at the coffee shop, if necessary. So your dire scenario is off the mark." But that clearly isn't an accurate statement unless it applies to the majority of patients taking Ibalizumab. Misiu was correct when she said it would be a major inconvenience for most patients. But I digress, because this is really a moot point and not my concern since I firmly believe the company will be sold long before PRO 140 becomes a competitor.

And I'm just curious - where did you see that the company will make 30% rather than 60% margin?

I understand that, but will insurance companies pay for an RN to make a house call or visit the cafe to administer an IV for convenience? Of course not. If that was the case, nobody would go to the hospital for an infusion.

To be honest with you, I really think this is a moot point, because Cytodyn will be sold long before it get's to market, so it's really not an issue for Pro 140.

"The company is setting up the program, not the insurance companies." That only means they are setting up the program to provide the service to patients who request it, but services are NOT free. Do you really think there's not going to be an extra charge for that service, and they're doing it out of the goodness of their hearts?

I suspect the company came up with this option to smooth the ruffled feathers of investors, but common sense tells me this isn't going to be a practical option for most of their patients.

And who do you think is going to pay for that convenience - the insurance companies? Yeah, I don't think so. Insurance companies don't like to pay extra for conveniences. This means patients are going to have to pay out of pocket for an RN to come to your home, at work or at the coffee shop. And I suspect most patients can't afford that luxury.

And BTW, RNs aren't cheap - I'm married to one!

Whereas some people fear dilution, I'm actually hoping that it will happen soon because I think the delay is helping to keep the sp down due to many investors, like Fred, who are sitting on the sidelines out of the concern that it will hurt the sp. We're way too close to getting the PE combo results for dilution to have any long-term effect. And given that all recent cash raises were relatively small, I believe mgmt will continue to try to ride the waves, and only further dilute to raise just enough cash to cover us to the next event, which may be when they release the PE data, or the end of Oct (due to the Oct 17 meeting with the FDA). And in late Oct or early Nov, I would expect another minor dilution to get us to the end of the year when they expect to complete enrollment for the mono trial. Why raise a significant amount of cash now if they may not need it due to a BO which could happen at any time? This is all speculation on my part, but I've been here long enough to see how mgmt is playing the game. I also think there's much more risk in sitting on the sidelines and missing out on a possible BO, than experiencing future dilution that will continue to fund two ongoing P3 trials for a drug that may be worth billions in future revenue to a BP. I realize everyone has their own level of risk tolerance, but one has to decide which is more riskier - missing out on a binary event, or future dilution.

I couldn't agree with you more, Axe! IMO, my interpretation of this PR is the rocket's on the launch pad and all systems are "GO"!

LOL, oh so true! I'll have to remember that...

Yet you assume everything that is not stated is bad? Sure, everyone knows that companies release PR's on Monday morning before the opening bell because things are looking bad.

And given that "eleven patients have completed the full 25-week protocol with undetectable viral loads and "Ten patients are currently in a rollover study after completing the 25-week trial." You don't think that gives a hint as to whether they met their PEs?

And things are looking so bad, they're going to meet with the FDA "to discuss the next steps in CytoDyn’s efforts towards the analysis of primary efficacy endpoint" and filing of a Biologics License Application for PRO 140." Why would they have a discussion with the FDA about the filing of a BLA if they didn't meet their PEs?

Perhaps you're not familiar with the mono trial. It's OPEN LABEL which means the data can be viewed at any time with an NDA. The trial started over 8 months ago and they've already enrolled over a 100 patients, which means by the end of the year, they'll have at a minimum 5 months of data for over a 100 patients for mono.


The timing for making a BO offer isn't based off of the current mc or sp. That's not where the risk is when making a purchase. The timing and price is based off of future revenue potential, and the risk of losing the opportunity to a competitor. The longer they wait, the higher the risk - especially after the PE results for adjunct are announced, which can happen any time.

So, is Fred off today?

Why would there be a selling strategy for the drug? Their strategy is to sell the company - not the drug. If the adjunct trial is successful, as most of us believe it will be, it will exponentially increase their odds of finding a buyer. And the buyer will be more focused on the selling strategy for mono, not combo.

Fred, your agenda has become painfully clear. Good luck on trying to tamp down everyone's excitement about the coming binary events for CYDY. I wish I could say the same about your stock. But not everyone can pick a winning stock, especially those who lose over 60% in their investment in less than a month. But IMO, here's your chance to gain some of that back.

BTW, I have no intention of going over to your board and attempting to tamp down their spirits. It just doesn't seem like much of a challenge, and the bag holders over their are depressed enough as it is. I just saw the announcement that just showed up about 45 minutes ago - "Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the Firm".

I didn't see the contact information, so you may want to Google the firm's name for their contact information.

Good luck and thanks for stopping by.

By the way Fred, I'd be happy to take you up on your offer to have a discussion with you on the IPCI board, but I'm really not interested in a stock that's dropped more than 60% in a month. There's way too much risk involved in that stock, but just my opinion. I'd rather continue our discussions here on the CYDY board where they're relevant, and there's much less risk that's associated with the sp. But thanks for asking!

I still don't see it Fred. Are you referring to where it says "The Company has been in ongoing dialogue with the U.S. Food and Drug Administration (FDA) regarding the number of patients enrolled in the trial." That's been going on since the beginning of the trial, however I suspect you already know that. If so, I'm not sure how you can construe it to mean they're now trying to alter the number of patients and data analysis. That's quite a leap.

Or were you referring to where it says "We are optimistic about achieving the primary efficacy endpoint in this combination trial given our prior clinical experience with PRO 140."?

So now it's "bankruptcy is not out of the question as the company likely has little cash left". Yikes, Fred - it sounds like the Bears have taken control. So do you think we should all jump ship now and get out? But where could we invest if we sell our shares in CYDY? Any suggestions, Fred?

Fred, who said they are trying to alter the number of patients and data analysis? Can you share the link?

TIA

Nobody's attacking you, Fred. I just made a legitimate observation which raised a legitimate question, and that was to give you the opportunity to compare the two, since you seem to be so negative on CYDY while being so optimistic about IPCI. No need to take it personally. I'm just curious as to why you feel the need to share your concerns about CYDY even though, according to you, you wouldn't own any shares at this time. It would seem to me that your time would be better spent on the other board where you appear to be optimistic following the 60% drop. So, I think it's fair to ask how you would compare the two.

Wow - that's quite a dive into the dismal abyss, Fred. So now you're convinced the data is bad and you're concerned about their ability to get additional funding to continue their P3 trials.

But then I read your recent posts on the IPCI board where you seem so optimistic about their HIV product even though the sp has dropped over 60% in the last month, and you seem to think it's due to sp manipulation?

So how would you compare the two, Fred?

The volume is very low today, which tells me someone's probably just selling some shares to generate some cash.

Fred, in your opening sentence, you said "Press release statements should be read very carefully and it is always difficult to overcome your own biases when interpreting the words." And then in your closing comment, you said "the bottom line from my perspective is the timelines have been pushed out across the board".

Yes, I agree with you about PRs. It is always difficult to overcome your own biases when interpreting the words.

This is great news that they've enrolled 33 patients for combo. The FDA only required 30 for combo, so this means they'll be giving the FDA more than what they asked for when they meet with the FDA. Also, it sounds like they're still on-track for completing enrollment for mono by the end of they year, despite what others will have you think.

You have?? Not from what I've been reading. You said they didn't enroll the 30th patient by the end of June - where is your proof that you were correct? I suspect they enrolled the 30th patient by June 30th and enrolled 3 more in July. I guess I, too, can say "Well I have been right till now on timing".

If the seller sold at the bid price, it was a SELL. If you bought at the ask price, it was a BUY.

I got an email from eTrade on Friday, and also voted "no" to a RS.

Excellent point, Nation. I just added your post as a 'Sticky'.
And welcome to the CYDY board!

...are you sure about that?

Thanks for the update, Saltz. Do you know if the "last two" patients were numbers 29 & 30, or if they were in addition to the 30 patients so they would have extras in case any patients dropped out?

I suspect just the opposite. The sp often closes up on Fridays following the mid-week dip. PRs are often released prior to the opening bell on Mondays, especially if they're positive, and most investors don't want to be out over the weekends. That's why I picked up an additional 20k shares today.

Um...you may want to do a little DD before you start the name calling. They did the same thing last year but didn't issue a r/s. This is nothing new.

Only stockholders of record at the close of business on July 11, 2016, will be entitled to notice of and to vote at the Annual Meeting or any postponements or adjournments thereof.
The Annual Meeting is being held to consider and vote on the following matters:

1. Election of seven directors;

2. Approval of a proposal to amend the Company’s Certificate of Incorporation to increase the total number of authorized shares of common stock from 250,000,000 shares to 350,000,000 shares;

3. Approval of a reverse stock split at a ratio of any whole number between one-for-two and one-for-eight, as determined by our board of directors, at any time before August 24, 2017, if and as determined by our board of directors;

4. Ratification of the selection of Warren Averett, LLC as the Company’s independent registered public accounting firm for the fiscal year ending May 31, 2017;

5. A non-binding advisory vote to approve our executive compensation; and

6. The transaction of any other business as may properly come before the Annual Meeting or any postponements or adjustments thereof.

There's nothing to debate - the "fact" that they haven't issued a PR means...actually, nothing.

Your "presumption"?? Sunday you said it was a "fact".

Fact or fiction? Appears to be the latter. The reality of it is unless you have inside information, neither you nor I know if they've completed enrollment. And when did they say they would issue a PR immediately after enrolling the 30th patient? Send me the link please.

LOL - "the" presumption is? Who is "the"? Maybe "you" but not "me" or many others on this board. Why would a company issue a PR within hours after enrolling the last patient and not wait until after the PE is completed? What would happen if the 30th patient dropped out the day after enrollment? That would be like Comey saying Hillary isn't under investigation a couple of months before the election. What's funnier is that some people on this board are trying to convince other investors that it's a bad omen to not get a PR within the first hours or days following Q2. The company said only a month ago they expected to complete enrollment in Q2. "My" presumption is they completed enrollment UNLESS we hear otherwise. And if they didn't, and they need another week or two, that's fine with me. I want them to get it right and not make a rushed announcement to appease a couple of posters on a MB.

This is just my opinion, but if I was a glass half-empty type of person and suspected the worse, I would sell all of my shares and get out now. But if I was a glass half-full type if person, which I am, I would be excited about the next couple of weeks and months.

Can you show evidence that enrollment is NOT complete? IMO, if you're going to cover your shorts, this is probably the time to do it.

Most brokerages won't allow margin to be used for shorting OTC stocks. Again, I said "most", not "all".

You also said "Oct 2015 start of enrollment - not completed 30 patient enrollment as of Jun 30 2017 - fact".
Fact? I must have missed that. Can you please post the link that points to this "fact", or tell us who on the inside shared this "fact" with you? Thanks in advance.

Here's another scenario. They're in talks with BP(s) and aren't concerned about the current sp. We can all make assumptions, but the reality of it is that nobody on this mb knows what's best for the company or investors without inside information, which I "assume" you don't have.

Yawn...here we go again. Who said they didn't complete enrollment by 6/30? Can you post the link? Or are you just assuming again?

Why would any reasonable person be expecting a press release today? When did anyone say they would issue a PR the minute they enroll the 30th patient? It sounds to me like a lot of posters showed up today to set unreasonable expectations, which ironically coincides with the significant increase in sp this week. Hmm...

It sounds like his "shorts" are on fire...LOL

Did you forget about BTD? The reason they've applied for BTD, and will probably receive, is to speed up the FDA review and approval process. And given Trump's plan to streamline the FDA approval process, I don't think we'll see 2019. But given that we'll probably be bought well before the end of 2018, this is all moot anyway.